Publications by authors named "A K Erbe"
Radiopharmaceutical therapy (RPT) enhances tumor response to immune checkpoint inhibitors (ICI) in preclinical models, but the effects of different radioisotopes have not been thoroughly compared. To evaluate mechanisms of response to RPT+ICI, we used NM600, an alkylphosphocholine selectively taken up by most tumors. Effects of Y-, Lu-, and Ac-NM600 + ICIs were compared in syngeneic murine models, B78 melanoma (poorly immunogenic) and MC38 colorectal cancer (immunogenic).
View Article and Find Full Text PDFArticle Synopsis
- Ultradense peptide binding arrays provide a means to study millions of peptides in serum samples, enhancing our understanding of immune responses through antibody profiling.
- The HERON R package was developed to identify immunogenic epitopes and analyze antibody targets across multiple samples while estimating their significance at different biological levels.
- HERON is competitive in identifying key antibody regions for diagnostics and treatment, and it's available for use on Bioconductor at the provided link.
Introduction: Lactate is a pivotal molecule with diverse functions in the metabolic reprogramming of cancer cells. Beyond its role in metabolism, lactate exerts a modulatory effect within the tumor microenvironment; it is utilized by stromal cells and has been implicated in the suppression of the immune response against the tumor.
Methods: Using assays (including flow cytometry, live-cell imaging and metabolic analyses), the impact of lactate dehydrogenase inhibitors (LDHIs) on melanoma cells were assessed.
Plastic pollution is an increasing problem in the marine environment, and microplastics are frequently ingested by wildlife, including seabirds. Faeces are an increasingly used matrix to quantify egested microplastics. We investigated microplastics in 36 faeces samples from chicks of European shags (Gulosus aristotelis) sampled at Sklinna, central Norway in 2021.
View Article and Find Full Text PDFBackground: The majority of experimental approaches for cancer immunotherapy are tested against relatively small tumors in tumor-bearing mice, because in most cases advanced cancers are resistant to the treatments. In this study, we asked if even late-stage mouse tumors can be eradicated by a rationally designed combined radio-immunotherapy (CRI) regimen.
Methods: CRI consisted of local radiotherapy, intratumoral IL-12, slow-release systemic IL-2 and anti- CTLA-4 antibody.